News

Takeda has licensed exclusive rights to use ImmunoGen’s antibody-drug conjugate (ADC) technology including its new DNA-acting IGN payload agents to develop and commercialize targeted anticancer therapeutics to up

Based in the recently reported nonclinical results, the company intends to start dosing in a Phase II trial of vepoloxamer in patients with chronic heart failure in the

Under the deal, scientists at CSHL and GSK will pursue drug development based on a new approach to regulate the enzymatic activity of the phosphatase PTP1B. The multiyear

Earlier in January, the company secured approval from the US Food and Drug Administration (FDA) for a new drug application (NDA) for the product. For the twelve months

As additional support to the clinical program for ALZ-801, the company had reported expanded post-hoc analyses of Phase III data with tramiprosate. Tramiprosate is the parent molecule of

As part of the deal, both the firms will support the development and potential commercialization of at least three cancer treatments over the next decade. The agreement also

In Japan, Repatha is being developed by Amgen Astellas BioPharma, a joint venture between Amgen and Astellas Pharma, a Japanese pharmaceutical firm. Repatha inhibits proprotein convertase subtilisin/kexin type

The ongoing Phase Ib randomized, double-blind, placebo-controlled, multiple-dose PRIME trial is evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of aducanumab. The interim analysis of PRIME reflects

Currently, the company is in the final stage of study preparation for a Phase II trial in SCD with sevuparin and intends to begin patient enrollment during the